HER-2 positive	Salivary Gland Cancer	HER-2 positive	Salivary Gland Cancer	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1
PD-L1 expression	Salivary Gland Cancer	PD-L1 expression	Salivary Gland Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Salivary Gland Cancer	No biomarker	Salivary Gland Cancer	cisplatin + doxorubicin hydrochloride + cyclophosphamide Sensitive: A2 - Guideline cisplatin + doxorubicin hydrochloride + cyclophosphamide Sensitive : A2	cisplatin + doxorubicin hydrochloride + cyclophosphamide Sensitive: A2 - Guideline cisplatin + doxorubicin hydrochloride + cyclophosphamide Sensitive : A2
No biomarker	Salivary Gland Cancer	No biomarker	Salivary Gland Cancer	cisplatin + vinorelbine tartrate Sensitive: A2 - Guideline cisplatin + vinorelbine tartrate Sensitive : A2	cisplatin + vinorelbine tartrate Sensitive: A2 - Guideline cisplatin + vinorelbine tartrate Sensitive : A2
NTRK2 fusion	Salivary Gland Cancer	NTRK2 fusion	Salivary Gland Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK1 fusion	Salivary Gland Cancer	NTRK1 fusion	Salivary Gland Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK3 fusion	Salivary Gland Cancer	NTRK3 fusion	Salivary Gland Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK3 fusion	Salivary Gland Cancer	NTRK3 fusion	Salivary Gland Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK1 fusion	Salivary Gland Cancer	NTRK1 fusion	Salivary Gland Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK2 fusion	Salivary Gland Cancer	NTRK2 fusion	Salivary Gland Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
AR positive	Salivary Gland Cancer	AR positive	Salivary Gland Cancer	leuprolide acetate Sensitive: A2 - Guideline leuprolide acetate Sensitive : A2	leuprolide acetate Sensitive: A2 - Guideline leuprolide acetate Sensitive : A2
AR positive	Salivary Gland Cancer	AR positive	Salivary Gland Cancer	bicalutamide Sensitive: A2 - Guideline bicalutamide Sensitive : A2	bicalutamide Sensitive: A2 - Guideline bicalutamide Sensitive : A2

Salivary Gland Cancer

Associations(57)

Associations
(57)